Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)

References

• Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152:142–156.
   PubMed Web of Science ®Google Scholar
• Lusivika-Nzinga C, Fontaine H, Dorival C, et al. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. J Viral Hepat. 2019;26:1489–1492.
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline Cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264–1278.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T, et al. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study. Liver Int. 2019;39:448–454.
   PubMed Web of Science ®Google Scholar
• Noureddin M, Sanyal AJ. Pathogenesis of NASH: the impact of multiple pathways. Curr Hepatol Rep. 2018;17:350–360.
   PubMedGoogle Scholar
• Handschumacher RE, Harding MW, Rice J, et al. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984;226:544–547.
   PubMed Web of Science ®Google Scholar
• Fischer G, Bang H, Mech C. Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides. Biomed Biochim Acta. 1984;43:1101–1111.
   PubMedGoogle Scholar
• Lensmeyer GL, Wiebe DA, Carlson IH, et al. Concentrations of cyclosporin A and its metabolites in human tissues postmortem. J Anal Toxicol. 1991;15:110–115.
   PubMed Web of Science ®Google Scholar
• Wagner O, Schreier E, Heitz F, et al. Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug Metab Dispos. 1987;15:377–383.
   PubMed Web of Science ®Google Scholar
• Bruelisauer A, Kawai R, Misslin P, et al. Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration. Drug Metab Dispos. 1994;22:194–199.
   PubMed Web of Science ®Google Scholar
• Naoumov NV. Cyclophilin inhibition as potential therapy for liver diseases. J Hepatol. 2014;61:1166–1174.
   PubMed Web of Science ®Google Scholar
• Pal D, Chakrabarti P. Cis peptide bonds in proteins: residues involved, their conformations, interactions and locations. J Mol Biol. 1999;294:271–288.
   PubMed Web of Science ®Google Scholar
• Schmidpeter PAM, Koch JR, Schmid FX. Control of protein function by prolyl isomerization. Biochim Biophys Acta. 2015;1850:1973–1982.
   PubMed Web of Science ®Google Scholar
• Lu KP, Finn G, Lee TH, et al. Prolyl cis-trans isomerization as a molecular timer. Nat Chem Biol. 2007;3:619–629.
   PubMed Web of Science ®Google Scholar
• Sarkar P, Reichman C, Saleh T, et al. Proline cis-trans isomerization controls autoinhibition of a signaling protein. Mol Cell. 2007;25:413–426.
   PubMed Web of Science ®Google Scholar
• Lummis SCR, Beene DL, Lee LW, et al. Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. Nature. 2005;438:248–252.
   PubMed Web of Science ®Google Scholar
• Sarkar P, Saleh T, Tzeng SR, et al. Structural basis for regulation of the Crk signaling protein by a proline switch. Nat Chem Biol. 2011;7:51–57.
   PubMed Web of Science ®Google Scholar
• Aumüller T, Jahreis G, Fischer G, et al. Role of prolyl cis/trans isomers in cyclophilin-assisted Pseudomonas syringae AvrRpt2 protease activation. Biochemistry. 2010;49:1042–1052.
   PubMed Web of Science ®Google Scholar
• Davis TL, Walker JR, Campagna-Slater V, et al. Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases. PLoS Biol. 2010;8:e1000439.
   PubMed Web of Science ®Google Scholar
• Ullah Dawar F, Tu J, Nasir Khan Khattak M, et al. Cyclophilin A: a key factor in virus replication and potential target for anti-viral therapy. Curr Issues Mol Biol. 2017;21:1–20.
   PubMed Web of Science ®Google Scholar
• Fischer G, Wittmann-liebold B, Lang K, et al. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature. 1989;337:476–478.
   PubMed Web of Science ®Google Scholar
• Cung -T-T, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015;373:1021–1031.
   PubMed Web of Science ®Google Scholar
• Monassier L, Ayme-Dietrich E, Aubertin-Kirch G, et al. Targeting myocardial reperfusion injuries with cyclosporine in the CIRCUS trial - pharmacological reasons for failure. Fundam Clin Pharmacol. 2016;30:191–193.
   PubMed Web of Science ®Google Scholar
• Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473–481.
   PubMed Web of Science ®Google Scholar
• Upadhaya S, Madala S, Baniya R, et al. Impact of cyclosporine A use in the prevention of reperfusion injury in acute myocardial infarction: A meta-analysis. Cardiol J. 2017;24:43–50.
   PubMed Web of Science ®Google Scholar
• Merlini L, Angelin A, Tiepolo T, et al. Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Natl Acad Sci. 2008;105:5225–5229.
   PubMed Web of Science ®Google Scholar
• Merlini L, Sabatelli P, Armaroli A, et al. Cyclosporine A in Ullrich congenital muscular dystrophy: long-term results. Oxid Med Cell Longev. 2011;2011:139194.
   PubMedGoogle Scholar
• Sigal NH, Dumont F, Durette P, et al. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med. 1991;173:619–628.
   PubMed Web of Science ®Google Scholar
• Quesniaux VFJ, Schreier MH, Wenger RM, et al. Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. Eur J Immunol. 1987;17:1359–1365.
   PubMed Web of Science ®Google Scholar
• Sweeney ZK, Fu J, Wiedmann B. From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds. J Med Chem. 2014;57:7145–7159.
   PubMed Web of Science ®Google Scholar
• Hopkins S, Dimassimo B, Rusnak P, et al. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol. 2012;57:47–54.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Godofsky E, Rouzier R, et al. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res. 2011;89:238–245.
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M-M, Flisiak R, Sarin SK, et al. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology. 2015;62:1013–1023.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Flisiak R, Vierling JM, et al. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015;42:829–844.
   PubMed Web of Science ®Google Scholar
• Buti M, Flisiak R, Kao JH, et al. Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a phase II trial. J Viral Hepat. 2015;22:596–606.
   PubMed Web of Science ®Google Scholar
• Baugh J, Gallay P. Cyclophilin involvement in the replication of hepatitis C virus and other viruses. Biol Chem. 2012;393:579–587.
   PubMed Web of Science ®Google Scholar
• Fu J, Tjandra M, Becker C, et al. Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition. J Med Chem. 2014;57:8503–8516.
   PubMed Web of Science ®Google Scholar
• Prell E, Kahlert V, Rücknagel KP, et al. Fine tuning the inhibition profile of cyclosporine a by derivatization of the MeBmt residue. ChemBioChem. 2013;14:63–65.
   PubMed Web of Science ®Google Scholar
• Malešević M, Kühling J, Erdmann F, et al. A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins. Angew Chem Int Educ. 2010;49:213–215.
   PubMed Web of Science ®Google Scholar
• Malouitre S, Dube H, Selwood D, et al. Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation. Biochem J. 2010;425:137–148.
   Web of Science ®Google Scholar
• Gallay PA, Bobardt MD, Chatterji U, et al. The novel cyclophilin inhibitor CPI-431-32 concurrently blocks HCV and HIV-1 infections via a similar mechanism of action. PLoS One. 2015;10:e0134707.
   PubMed Web of Science ®Google Scholar
• Gallay PP, Ure D, Bobardt M, et al. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice. PLoS One. 2019;14:e0217433.
   PubMed Web of Science ®Google Scholar
• Kuo J, Bobardt M, Chatterji U, et al. A pan-cyclophilin inhibitor, CRV431, decreases fibrosis and tumor development in chronic liver disease models. J Pharmacol Exp Ther. 2019;371:231–241.
   PubMed Web of Science ®Google Scholar
• Gregory MA, Bobardt M, Obeid S, et al. Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. Antimicrob Agents Chemother. 2011;55:1975–1981.
   PubMed Web of Science ®Google Scholar
• Moss SJ, Bobardt M, Leyssen P, et al. Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection. Medchemcomm. 2012;3:938–943.
   Web of Science ®Google Scholar
• Hansson MJ, Moss SJ, Bobardt M, et al. Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection. Chem Biol. 2015;22:285–292.
   PubMedGoogle Scholar
• Mackman RL, Steadman VA, Dean DK, et al. Discovery of a potent and orally bioavailable cyclophilin inhibitor derived from the sanglifehrin macrocycle. J Med Chem. 2018;61:9473–9499.
   PubMed Web of Science ®Google Scholar
• Briston T, Selwood DL, Szabadkai G, et al. Mitochondrial permeability transition: a molecular lesion with multiple drug targets. Trends Pharmacol Sci. 2019;40:50–70.
   PubMed Web of Science ®Google Scholar
• Park I, Londhe AM, Lim JW, et al. Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in Aβ-induced mitochondrial dysfunction. J Comput Aided Mol Des. 2017;31:929–941.
   PubMed Web of Science ®Google Scholar
• Valasani KR, Sun Q, Fang D, et al. Identification of a small molecule cyclophilin D inhibitor for rescuing Aβ-mediated mitochondrial dysfunction. ACS Med Chem Lett. 2016;7:294–299.
   PubMed Web of Science ®Google Scholar
• Nevers Q, Ruiz I, Ahnou N, et al. Characterization of the anti-hepatitis C virus activity of new nonpeptidic small-molecule cyclophilin inhibitors with the potential for broad anti-flaviviridae activity. Antimicrob Agents Chemother. 2018;62:e00126-18.
   Web of Science ®Google Scholar
• Zhao X, Xia C, Wang X, et al. Cyclophilin J PPIase inhibitors derived from 2,3-quinoxaline-6 amine exhibit antitumor activity. Front Pharmacol. 2018;9:1–11.
   PubMed Web of Science ®Google Scholar
• Panel M, Ruiz I, Brillet R, et al. Small-molecule inhibitors of cyclophilins block opening of the mitochondrial permeability transition pore and protect mice from hepatic ischemia/reperfusion injury. Gastroenterology. 2019;157:1368–1382.
   PubMed Web of Science ®Google Scholar
• Lu W, Cheng F, Yan W, et al. Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA. Oncogene. 2017;36:4719–4731.
   PubMed Web of Science ®Google Scholar
• Ni S, Yuan Y, Huang J, et al. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach. J Med Chem. 2009;52:5295–5298.
   PubMed Web of Science ®Google Scholar
• Shore ER, Awais M, Kershaw NM, et al. Small molecule inhibitors of cyclophilin D to protect mitochondrial function as a potential treatment for acute pancreatitis. J Med Chem. 2016;59:2596–2611.
   PubMed Web of Science ®Google Scholar
• Porter GA, Beutner G. Cyclophilin D, somehow a master regulator of mitochondrial function. Biomolecules. 2018;8:176.
   Web of Science ®Google Scholar
• Wang X, Du H, Shao S, et al. Cyclophilin D deficiency attenuates mitochondrial perturbation and ameliorates hepatic steatosis. Hepatology. 2018;68:62–77.
   PubMed Web of Science ®Google Scholar
• Su X, Lin D, Luo D, et al. Cyclophilin D participates in the inhibitory effect of high‐fat diet on the expression of steroidogenic acute regulatory protein. J Cell Mol Med. 2019;23:6859–6871.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Qu H, Xiong X, et al. Deficiency of mitochondrial glycerol 3‐phosphate dehydrogenase contributes to hepatic steatosis. Hepatology. 2019;70:84–97.
   PubMed Web of Science ®Google Scholar
• Greene NP, Lee DE, Brown JL, et al. Mitochondrial quality control, promoted by PGC-1 α, is dysregulated by Western diet-induced obesity and partially restored by moderate physical activity in mice. Physiol Rep. 2015;3:e12470.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25:486–541.
   PubMed Web of Science ®Google Scholar
• Elrod JW, Molkentin JD. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J. 2013;77:1111–1122.
   PubMed Web of Science ®Google Scholar
• Tapley DF. The effect of thyroxine and other substances on the swelling of isolated rat liver mitochondria. J Biol Chem. 1956;222:325–339.
   PubMed Web of Science ®Google Scholar
• Chappell J, Crofts A. Calcium ion accumulation and volume changes of isolated liver mitochondria. Calcium ion-induced swelling. Biochem J. 1965;95:378–386.
   PubMed Web of Science ®Google Scholar
• Hunter DR, Haworth RA, Southard JH. Relationship between configuration, function, and permeability in calcium-treated mitochondria. J Biol Chem. 1976;251:5069–5077.
   PubMed Web of Science ®Google Scholar
• Lehninger AL. Reversal of various types of mitochondrial swelling by adenosine triphosphate. J Biol Chem. 1959;234:2465–2471.
   PubMed Web of Science ®Google Scholar
• Hunter DR, Haworth RA. The Ca2+-induced membrane transition in mitochondria. III. Transitional Ca2+ release. Arch Biochem Biophys. 1979;195:468–477.
   PubMed Web of Science ®Google Scholar
• Halestrap AP, Richardson AP. The mitochondrial permeability transition: A current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol. 2015;78:129–141.
   PubMed Web of Science ®Google Scholar
• Alam MR, Baetz D, Ovize M. Cyclophilin D and myocardial ischemia-reperfusion injury: A fresh perspective. J Mol Cell Cardiol. 2015;78:80–89.
   PubMed Web of Science ®Google Scholar
• Shang W, Gao H, Lu F, et al. Cyclophilin D regulates mitochondrial flashes and metabolism in cardiac myocytes. J Mol Cell Cardiol. 2016;91:63–71.
   PubMed Web of Science ®Google Scholar
• Hüser J, Blatter LA. Fluctuations in mitochondrial membrane potential caused by repetitive gating of the permeability transition pore. Biochem J. 1999;343(Pt 2):311–317.
   PubMedGoogle Scholar
• Lu X, Kwong JQ, Molkentin JD, et al. Individual cardiac mitochondria undergo rare transient permeability transition pore openings. Circ Res. 2016;118:834–841.
   PubMed Web of Science ®Google Scholar
• Korge P, Yang L, Yang J-H, et al. Protective role of transient pore openings in calcium handling by cardiac mitochondria. J Biol Chem. 2011;286:34851–34857.
   PubMed Web of Science ®Google Scholar
• Connern CP, Halestrap AP. Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel. Biochem J. 1994;302(Pt 2):321–324.
   PubMedGoogle Scholar
• Matas J, Tien Sing Young N, Bourcier-Lucas C, et al. Increased expression and intramitochondrial translocation of cyclophilin-D associates with increased vulnerability of the permeability transition pore to stress-induced opening during compensated ventricular hypertrophy. J Mol Cell Cardiol. 2009;46:420–430.
   PubMed Web of Science ®Google Scholar
• Eliseev RA, Filippov G, Velos J, et al. Role of cyclophilin D in the resistance of brain mitochondria to the permeability transition. Neurobiol Aging. 2007;28:1532–1542.
   PubMed Web of Science ®Google Scholar
• Denton RM. Regulation of mitochondrial dehydrogenases by calcium ions. Biochim Biophys Acta - Bioenergy. 2009;1787:1309–1316.
   PubMed Web of Science ®Google Scholar
• Glancy B, Balaban RS. Role of mitochondrial Ca 2+ in the regulation of cellular energetics. Biochemistry. 2012;51:2959–2973.
   PubMed Web of Science ®Google Scholar
• Elrod JW, Wong R, Mishra S, et al. Cyclophilin D controls mitochondrial pore–dependent Ca2+ exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest. 2010;120:3680–3687.
   PubMed Web of Science ®Google Scholar
• Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658–662.
   PubMed Web of Science ®Google Scholar
• Tavecchio M, Lisanti S, Bennett MJ, et al. Deletion of cyclophilin D impairs β-oxidation and promotes glucose metabolism. Sci Rep. 2015;5:1–11.
   Web of Science ®Google Scholar
• Klawitter J, Pennington A, Klawitter J, et al. Mitochondrial cyclophilin D ablation is associated with the activation of Akt/p70S6K pathway in the mouse kidney. Sci Rep. 2017;7:10540.
   PubMed Web of Science ®Google Scholar
• Menazza S, Wong R, Nguyen T, et al. CypD−/− hearts have altered levels of proteins involved in Krebs cycle, branch chain amino acid degradation and pyruvate metabolism. J Mol Cell Cardiol. 2013;56:81–90.
   PubMed Web of Science ®Google Scholar
• Shum LC, White NS, Nadtochiy SM, et al. Cyclophilin D knock-out mice show enhanced resistance to osteoporosis and to metabolic changes observed in aging bone. PLoS One. 2016;11:1–18.
   Web of Science ®Google Scholar
• Klawitter JJ, Klawitter JJ, Pennington A, et al. Cyclophilin D knockout protects the mouse kidney against cyclosporin A-induced oxidative stress. Am J Physiol Physiol. 2019;317:F683–94.
   PubMed Web of Science ®Google Scholar
• Nguyen TTM, Wong R, Menazza S, et al. Cyclophilin D modulates mitochondrial acetylome. Circ Res. 2013;113:1308–1319.
   PubMed Web of Science ®Google Scholar
• Theurey P, Tubbs E, Vial G, et al. Mitochondria-associated endoplasmic reticulum membranes allow adaptation of mitochondrial metabolism to glucose availability in the liver. J Mol Cell Biol. 2016;8:129–143.
   PubMed Web of Science ®Google Scholar
• Beutner G, Alanzalon RE, Porter GA. Cyclophilin D regulates the dynamic assembly of mitochondrial ATP synthase into synthasomes. Sci Rep. 2017;7:14488.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Baetiong A, Kaufman H, et al. Improved exercise capacity in cyclophilin-D knockout mice associated with enhanced oxygen utilization efficiency and augmented glucose uptake via AMPK-TBC1D1 signaling nexus. Faseb J. 2019;33:11443–11457.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Bazarek S, Chandran B, et al. Cyclophilin-D: a resident regulator of mitochondrial gene expression. Faseb J. 2015;29:2734–2748.
   PubMed Web of Science ®Google Scholar
• Bernardi P, Rasola A, Forte M, et al. The mitochondrial permeability transition pore: channel formation by F-ATP synthase, integration in signal transduction, and role in pathophysiology. Physiol Rev. 2015;95:1111–1155.
   PubMed Web of Science ®Google Scholar
• Giorgio V, Bisetto E, Soriano ME, et al. Cyclophilin D modulates mitochondrial F0F1-ATP synthase by interacting with the lateral stalk of the complex. J Biol Chem. 2009;284:33982–33988.
   PubMed Web of Science ®Google Scholar
• Carraro M, Checchetto V, Szabó I, et al. F‐ ATP synthase and the permeability transition pore: fewer doubts, more certainties. FEBS Lett. 2019;593:1542–1553.
   PubMed Web of Science ®Google Scholar
• Leung AWC, Varanyuwatana P, Halestrap AP. The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. J Biol Chem. 2008;283:26312–26323.
   PubMed Web of Science ®Google Scholar
• Etzler JC, Bollo M, Holstein D, et al. Cyclophilin D over-expression increases mitochondrial complex III activity and accelerates supercomplex formation. Arch Biochem Biophys. 2017;613:61–68.
   PubMed Web of Science ®Google Scholar
• Paillard M, Tubbs E, Thiebaut P-A, et al. Depressing mitochondria-reticulum interactions protects cardiomyocytes from lethal hypoxia-reoxygenation injury. Circulation. 2013;128:1555–1565.
   PubMed Web of Science ®Google Scholar
• Vaseva AV, Marchenko ND, Ji K, et al. P53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell. 2012;149:1536–1548.
   PubMed Web of Science ®Google Scholar
• Lebedev I, Nemajerova A, Foda ZH, et al. A novel in vitro CypD-mediated p53 aggregation assay suggests a model for mitochondrial permeability transition by chaperone systems. J Mol Biol. 2016;428:4154–4167.
   PubMed Web of Science ®Google Scholar
• Barreto-Torres G, Hernandez JS, Jang S, et al. The beneficial effects of AMP kinase activation against oxidative stress are associated with prevention of PPARα-cyclophilin D interaction in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2015;308:H749–58.
   PubMed Web of Science ®Google Scholar
• Xi J, Wang H, Mueller RA, et al. Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore. Eur J Pharmacol. 2009;604:111–116.
   PubMed Web of Science ®Google Scholar
• Rasola A, Sciacovelli M, Chiara F, et al. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci U S A. 2010;107:726–731.
   PubMed Web of Science ®Google Scholar
• Fu M, Wan F, Li Z, et al. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2016;471:267–273.
   PubMed Web of Science ®Google Scholar
• Eliseev RA, Malecki J, Lester T, et al. Cyclophilin D interacts with Bcl2 and exerts an anti-apoptotic effect. J Biol Chem. 2009;284:9692–9699.
   PubMed Web of Science ®Google Scholar
• Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015;21:739–746.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–1192.
   PubMed Web of Science ®Google Scholar
• Taddeo EP, Laker RC, Breen DS, et al. Opening of the mitochondrial permeability transition pore links mitochondrial dysfunction to insulin resistance in skeletal muscle. Mol Metab. 2014;3:124–134.
   PubMed Web of Science ®Google Scholar
• Feng D, Tang Y, Kwon H, et al. High-fat diet-induced adipocyte cell death occurs through a cyclophilin D intrinsic signaling pathway independent of adipose tissue inflammation. Diabetes. 2011;60:2134–2143.
   PubMed Web of Science ®Google Scholar
• Laker RC, Taddeo EP, Akhtar YN, et al. The mitochondrial permeability transition pore regulator cyclophilin D exhibits tissue-specific control of metabolic homeostasis. PLoS One. 2016;11:1–12.
   Web of Science ®Google Scholar
• Fujimoto K, Chen Y, Polonsky KS, et al. Targeting cyclophilin D and the mitochondrial permeability transition enhances cell survival and prevents diabetes in Pdx1 deficiency. Proc Natl Acad Sci. 2010;107:10214–10219.
   PubMed Web of Science ®Google Scholar
• Tubbs E, Theurey P, Vial G, et al. Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin signaling and is implicated in hepatic insulin resistance. Diabetes. 2014;63:3279–3294.
   PubMed Web of Science ®Google Scholar
• Devalaraja-Narashimha K, Diener AM, Padanilam BJ. Cyclophilin D deficiency prevents diet-induced obesity in mice. FEBS Lett. 2011;585:677–682.
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Venugopal A, Sathisha K, et al. Proteomic profiling of high glucose primed monocytes identifies cyclophilin A as a potential secretory marker of inflammation in type 2 diabetes. Proteomics. 2012;12:2808–2821.
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Venugopal A, Kutty V, et al. Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease. Cardiovasc Diabetol. 2014;13:38.
   PubMed Web of Science ®Google Scholar
• Mutlu HH, Caklili OT, Coskunpinar E. Serum concentrations of cyclophilin A in patients with nonalcoholic fatty liver disease. Acta Gastroenterol Belg. 2017;80:3–7.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Z, Zhang B, et al. PPIA is a novel adipogenic factor implicated in obesity. Obesity. 2015;23:2093–2100.
   PubMed Web of Science ®Google Scholar
• Zhang H, Fan Q, Xie H, et al. Elevated serum cyclophilin B levels are associated with the prevalence and severity of metabolic syndrome. Front Endocrinol (Lausanne). 2017;8:360.
   PubMed Web of Science ®Google Scholar
• Hollie NI, Cash JG, Matlib MA, et al. Micromolar changes in lysophosphatidylcholine concentration cause minor effects on mitochondrial permeability but major alterations in function. Biochim Biophys Acta - Mol Cell Biol Lipids. 2014;1841:888–895.
   Web of Science ®Google Scholar
• Amaral AU, Cecatto C, da Silva JC, et al. cis-4-decenoic and decanoic acids impair mitochondrial energy, redox and Ca 2+ homeostasis and induce mitochondrial permeability transition pore opening in rat brain and liver: possible implications for the pathogenesis of MCAD deficiency. Biochim Biophys Acta - Bioenergy. 2016;1857:1363–1372.
   Web of Science ®Google Scholar
• Oyanagi E, Yano H, Kato Y, et al. L-carnitine suppresses oleic acid-induced membrane permeability transition of mitochondria. Cell Biochem Funct. 2008;26:778–786.
   PubMed Web of Science ®Google Scholar
• Palmeira CM, Rana MI, Frederick CB, et al. Induction of the mitochondrial permeability transition in vitro by short-chain carboxylic acids. Biochem Biophys Res Commun. 2000;272:431–435.
   PubMed Web of Science ®Google Scholar
• Rogers C, Davis B, Neufer PD, et al. A transient increase in lipid peroxidation primes preadipocytes for delayed mitochondrial inner membrane permeabilization and ATP depletion during prolonged exposure to fatty acids. Free Radic Biol Med. 2014;67:330–341.
   PubMed Web of Science ®Google Scholar
• Lablanche S, Cottet-Rousselle C, Lamarche F, et al. Protection of pancreatic INS-1 β-cells from glucose- and fructose-induced cell death by inhibiting mitochondrial permeability transition with cyclosporin A or metformin. Cell Death Dis. 2011;2:e134–e134.
   PubMed Web of Science ®Google Scholar
• Tonin AM, Amaral AU, Busanello ENB, et al. Long-chain 3-hydroxy fatty acids accumulating in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial trifunctional protein deficiencies uncouple oxidative phosphorylation in heart mitochondria. J Bioenerg Biomembr. 2013;45:47–57.
   PubMed Web of Science ®Google Scholar
• Cecatto C, Hickmann FH, Rodrigues MDN, et al. Deregulation of mitochondrial functions provoked by long-chain fatty acid accumulating in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial permeability transition deficiencies in rat heart - mitochondrial permeability transition pore opening a. Febs J. 2015;282:4714–4726.
   PubMed Web of Science ®Google Scholar
• Hickmann FH, Cecatto C, Kleemann D, et al. Uncoupling, metabolic inhibition and induction of mitochondrial permeability transition in rat liver mitochondria caused by the major long-chain hydroxyl monocarboxylic fatty acids accumulating in LCHAD deficiency. Biochim Biophys Acta - Bioenergy. 2015;1847:620–628.
   Web of Science ®Google Scholar
• Tominaga H, Katoh H, Odagiri K, et al. Different effects of palmitoyl- l -carnitine and palmitoyl-CoA on mitochondrial function in rat ventricular myocytes. Am J Physiol Circ Physiol. 2008;295:H105–12.
   PubMed Web of Science ®Google Scholar
• Sparagna GC, Hickson-Bick DL, Buja LM, et al. A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol. 2000;279:H2124–32.
   PubMed Web of Science ®Google Scholar
• Shibata H, Ichikawa T, Nakao K, et al. A high glucose condition sensitizes human hepatocytes to hydrogen peroxide-induced cell death. Mol Med Rep. 2008;1:379–385.
   PubMed Web of Science ®Google Scholar
• Yin X, Zheng F, Pan Q, et al. Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening. J Mol Endocrinol. 2015;55:169–181.
   PubMed Web of Science ®Google Scholar
• Düfer M, Krippeit-Drews P, Lembert N, et al. Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells. Mol Pharmacol. 2001;60:873–879.
   PubMed Web of Science ®Google Scholar
• Jiang M, Wang C, Meng Q, et al. Cyclosporin A attenuates weight gain and improves glucose tolerance in diet-induced obese mice. Mol Cell Endocrinol. 2013;370:96–102.
   PubMed Web of Science ®Google Scholar
• Fuhrmann A, Lopes P, Sereno J, et al. Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem Pharmacol. 2014;88:216–228.
   PubMed Web of Science ®Google Scholar
• Muduma G, Saunders R, Odeyemi I, et al. Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. PLoS One. 2016;11:e0160421.
   PubMed Web of Science ®Google Scholar
• Wissing KM, Abramowicz D, Weekers L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. Am J Transplant. 2018;18:1726–1734.
   PubMed Web of Science ®Google Scholar
• Stanciu C, Trifan A, Muzica C, et al. Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opin Pharmacother. 2019;20:379–384.
   PubMed Web of Science ®Google Scholar
• Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99–128.
   PubMed Web of Science ®Google Scholar
• Begriche K, Massart J, Robin M-A, et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58:1497–1507.
   PubMed Web of Science ®Google Scholar
• Mansouri A, Gattolliat C-H, Asselah T. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology. 2018;155:629–647.
   PubMed Web of Science ®Google Scholar
• Mota M, Banini BA, Cazanave SC, et al. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016;65:1049–1061.
   PubMed Web of Science ®Google Scholar
• Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765–783.
   PubMed Web of Science ®Google Scholar
• van der Graaff D, Kwanten WJ, Francque SM. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. Med Hypotheses. 2019;122:188–197.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Stevens MV, Kohr M, et al. Cysteine 203 of cyclophilin D is critical for cyclophilin D activation of the mitochondrial permeability transition pore. J Biol Chem. 2011;286:40184–40192.
   PubMed Web of Science ®Google Scholar
• Linard D, Kandlbinder A, Degand H, et al. Redox characterization of human cyclophilin D: identification of a new mammalian mitochondrial redox sensor? Arch Biochem Biophys. 2009;491:39–45.
   PubMed Web of Science ®Google Scholar
• Folda A, Citta A, Scalcon V, et al. Mitochondrial thioredoxin system as a modulator of cyclophilin D redox state. Sci Rep. 2016;6:23071.
   PubMed Web of Science ®Google Scholar
• López-Erauskin J, Galino J, Bianchi P, et al. Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. Brain. 2012;135:3584–3598.
   PubMed Web of Science ®Google Scholar
• Javadov S, Jang S, Parodi-Rullán R, et al. Mitochondrial permeability transition in cardiac ischemia–reperfusion: whether cyclophilin D is a viable target for cardioprotection? Cell Mol Life Sci. 2017;74:2795–2813.
   PubMed Web of Science ®Google Scholar
• Rehman H, Sun J, Shi Y, et al. NIM811 prevents mitochondrial dysfunction, attenuates liver injury, and stimulates liver regeneration after massive hepatectomy. Transplantation. 2011;91:406–412.
   PubMed Web of Science ®Google Scholar
• Fouzas I, Daoudaki M, Sotiropoulos GC, et al. Cyclosporine enhances liver regeneration: the role of hepatocyte MHC expression and PGE2–a study relevant to graft immunogenicity. Eur J Med Res. 2008;13:154–162.
   PubMed Web of Science ®Google Scholar
• Acar T, Ceyhan K, Qolakoglu T. Inhibition of apoptosis prevents liver failure and improves survival rates after extensive hepatectomy in rats. Acta Chir Belg. 2006;106:696–700.
   PubMed Web of Science ®Google Scholar
• Morii Y, Kawano K, Kim Y-I, et al. Augmentative effect of cyclosporin A on rat liver regeneration: influence on hepatocyte growth factor and transforming Growth factor-β1. Eur Surg Res. 1999;31:399–405.
   PubMed Web of Science ®Google Scholar
• Gao WY, Li D, Cai DE, et al. Hepatitis B virus X protein sensitizes HL-7702 cells to oxidative stress-induced apoptosis through modulation of the mitochondrial permeability transition pore. Oncol Rep. 2017;37:48–56.
   PubMed Web of Science ®Google Scholar
• Wang T, Weinman SA. Interactions between hepatitis C virus and mitochondria: impact on pathogenesis and innate immunity. Curr Pathobiol Rep. 2013;1:179–187.
   PubMedGoogle Scholar
• Tan C, Guo H, Zheng M, et al. Involvement of mitochondrial permeability transition in hepatitis B virus replication. Virus Res. 2009;145:307–311.
   PubMed Web of Science ®Google Scholar
• Clippinger AJ, Bouchard MJ. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J Virol. 2008;82:6798–6811.
   PubMed Web of Science ®Google Scholar
• Quarato G, D’Aprile A, Gavillet B, et al. The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction. Hepatology. 2012;55:1333–1343.
   PubMed Web of Science ®Google Scholar
• Rehman H, Ramshesh VK, Theruvath TP, et al. NIM811 (N-methyl-4-isoleucine cyclosporine), a mitochondrial permeability transition inhibitor, attenuates cholestatic liver injury but not fibrosis in mice. J Pharmacol Exp Ther. 2008;327:699–706.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Jaeschke H. Acetaminophen hepatotoxicity. Semin Liver Dis. 2019;39:221–234.
   PubMed Web of Science ®Google Scholar
• Kon K, Kim J-S, Jaeschke H, et al. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology. 2004;40:1170–1179.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Lebofsky M, Baines CP, et al. Cyclophilin D deficiency protects against acetaminophen-induced oxidant stress and liver injury. Free Radic Res. 2011;45:156–164.
   PubMed Web of Science ®Google Scholar
• King AL, Swain TM, Mao Z, et al. Involvement of the mitochondrial permeability transition pore in chronic ethanol-mediated liver injury in mice. Am J Physiol Liver Physiol. 2014;306:G265–77.
   PubMed Web of Science ®Google Scholar
• King AL, Swain TM, Dickinson DA, et al. Chronic ethanol consumption enhances sensitivity to Ca 2+ -mediated opening of the mitochondrial permeability transition pore and increases cyclophilin D in liver. Am J Physiol Liver Physiol. 2010;299:G954–66.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Ramshesh VK, Rehman H, et al. Acute ethanol causes hepatic mitochondrial depolarization in mice: role of ethanol metabolism. PLoS One. 2014;9:e91308.
   PubMed Web of Science ®Google Scholar
• Song MJ, Malhi H. The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease. Pharmacol Ther. 2019;203:107401.
   PubMed Web of Science ®Google Scholar
• Lebeaupin C, Vallée D, Hazari Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;69:927–947.
   PubMed Web of Science ®Google Scholar
• Ram BM, Ramakrishna G. Endoplasmic reticulum vacuolation and unfolded protein response leading to paraptosis like cell death in cyclosporine A treated cancer cervix cells is mediated by cyclophilin B inhibition. Biochim Biophys Acta Mol Cell Res. 2014;1843:2497–2512.
   PubMed Web of Science ®Google Scholar
• Siwecka N, Rozpędek W, Pytel D, et al. Dual role of endoplasmic reticulum stress-mediated unfolded protein response signaling pathway in carcinogenesis. Int J Mol Sci. 2019;20:4354.
   PubMed Web of Science ®Google Scholar
• Ciechomska IA, Gabrusiewicz K, Szczepankiewicz AA, et al. Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporine a-induced cell death. Oncogene. 2013;32:1518–1529.
   PubMed Web of Science ®Google Scholar
• Rao SR, Sundararajan S, Subbarayan R, et al. Cyclosporine-A induces endoplasmic reticulum stress and influences pro-apoptotic factors in human gingival fibroblasts. Mol Cell Biochem. 2017;429:179–185.
   PubMed Web of Science ®Google Scholar
• Choi Y-M, Cho H-Y, Anwar MA, et al. ATF3 attenuates cyclosporin A-induced nephrotoxicity by downregulating CHOP in HK-2 cells. Biochem Biophys Res Commun. 2014;448:182–188.
   PubMed Web of Science ®Google Scholar
• Groenendyk J, Paskevicius T, Urra H, et al. Cyclosporine A binding to COX-2 reveals a novel signaling pathway that activates the IRE1α unfolded protein response sensor. Sci Rep. 2018;8:16678.
   PubMed Web of Science ®Google Scholar
• Allaire M, Rautou P-E, Codogno P, et al. Autophagy in liver diseases: time for translation? J Hepatol. 2019;70:985–998.
   PubMed Web of Science ®Google Scholar
• Weiskirchen R, Tacke F. Relevance of autophagy in parenchymal and non-parenchymal liver cells for health and disease. Cells. 2019;8:16.
   PubMed Web of Science ®Google Scholar
• Sun T, Ding W, Xu T, et al. Parkin regulates programmed necrosis and myocardial ischemia/reperfusion injury by targeting cyclophilin-D. Antioxid Redox Signal. 2019;31:1177–1193.
   PubMed Web of Science ®Google Scholar
• Biczo G, Vegh ET, Shalbueva N, et al. Mitochondrial dysfunction, through impaired autophagy, leads to endoplasmic reticulum stress, deregulated lipid metabolism, and pancreatitis in animal models. Gastroenterology. 2018;154:689–703.
   PubMed Web of Science ®Google Scholar
• Fakharnia F, Khodagholi F, Dargahi L, et al. Prevention of cyclophilin D-mediated mPTP opening using cyclosporine-A alleviates the elevation of necroptosis, autophagy and apoptosis-related markers following global cerebral ischemia-reperfusion. J Mol Neurosci. 2017;61:52–60.
   PubMed Web of Science ®Google Scholar
• Gonçalves IO, Passos E, Diogo CV, et al. Exercise mitigates mitochondrial permeability transition pore and quality control mechanisms alterations in nonalcoholic steatohepatitis. Appl Physiol Nutr Metab. 2016;41:298–306.
   PubMed Web of Science ®Google Scholar
• Grumati P, Coletto L, Sabatelli P, et al. Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat Med. 2010;16:1313–1320.
   PubMed Web of Science ®Google Scholar
• Wang L, Gundelach JH, Bram RJ. Cycloheximide promotes paraptosis induced by inhibition of cyclophilins in glioblastoma multiforme. Cell Death Dis. 2017;8:e2807.
   PubMed Web of Science ®Google Scholar
• Feng W, Xin Y, Xiao Y, et al. Cyclophilin A enhances cell proliferation and xenografted tumor growth of early gastric cancer. Dig Dis Sci. 2015;60:2700–2711.
   PubMed Web of Science ®Google Scholar
• Eberhardt W, Nasrullah U, Pfeilschifter J. Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors. Cell Signal. 2018;52:1–11.
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang X, Nepovimova E, et al. Mechanism of cyclosporine A nephrotoxicity: oxidative stress, autophagy, and signalings. Food Chem Toxicol. 2018;118:889–907.
   PubMed Web of Science ®Google Scholar
• Priber J, Fonai F, Jakus PB, et al. Cyclophilin D disruption attenuates lipopolysaccharide-induced inflammatory response in primary mouse macrophages. Biochem Cell Biol. 2015;93:241–250.
   PubMedGoogle Scholar
• Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36:401–414.
   PubMed Web of Science ®Google Scholar
• Yeon SH, Yang G, Lee HE, et al. Oxidized phosphatidylcholine induces the activation of NLRP3 inflammasome in macrophages. J Leukoc Biol. 2017;101:205–215.
   PubMed Web of Science ®Google Scholar
• Soe NN, Sowden M, Baskaran P, et al. Acetylation of cyclophilin A is required for its secretion and vascular cell activation. Cardiovasc Res. 2014;101:444–453.
   PubMed Web of Science ®Google Scholar
• Kim K, Kim H, Jeong K, et al. Release of overexpressed CypB activates ERK signaling through CD147 binding for hepatoma cell resistance to oxidative stress. Apoptosis. 2012;17:784–796.
   PubMed Web of Science ®Google Scholar
• Jin ZG, Melaragno MG, Liao DF, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res. 2000;87:789–796.
   PubMed Web of Science ®Google Scholar
• Suzuki J, Jin Z-G, Meoli DF, et al. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res. 2006;98:811–817.
   PubMed Web of Science ®Google Scholar
• Billich A, Winkler G, Aschauer H, et al. Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J Exp Med. 1997;185:975–980.
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Kartha CC. Cyclophilin-A: a potential screening marker for vascular disease in type-2 diabetes. Can J Physiol Pharmacol. 2012;90:1005–1015.
   PubMed Web of Science ®Google Scholar
• Xue C, Sowden MP, Berk BC. Extracellular and intracellular cyclophilin A, native and post-translationally modified, show diverse and specific pathological roles in diseases. Arterioscler Thromb Vasc Biol. 2018;38:986–993.
   PubMed Web of Science ®Google Scholar
• Bahmed K, Henry C, Holliday M, et al. Extracellular cyclophilin-A stimulates ERK1/2 phosphorylation in a cell-dependent manner but broadly stimulates nuclear factor kappa B. Cancer Cell Int. 2012;12:1–13.
   PubMed Web of Science ®Google Scholar
• Damsker JM, Okwumabua I, Pushkarsky T, et al. Targeting the chemotactic function of CD147 reduces collagen-induced arthritis. Immunology. 2009;126:55–62.
   PubMed Web of Science ®Google Scholar
• Bukrinsky M. Extracellular cyclophilins in health and disease. Biochim Biophys Acta Gen Subj. 2015;1850:2087–2095.
   Web of Science ®Google Scholar
• Yurchenko V, Constant S, Eisenmesser E, et al. Cyclophilin-CD147 interactions: A new target for anti-inflammatory therapeutics. Clin Exp Immunol. 2010;160:305–317.
   PubMed Web of Science ®Google Scholar
• Yurchenko V, O’Connor M, Dai WW, et al. CD147 is a signaling receptor for cyclophilin B. Biochem Biophys Res Commun. 2001;288:786–788.
   PubMed Web of Science ®Google Scholar
• Pushkarsky T, Yurchenko V, Vanpouille C, et al. Cell surface expression of CD147/EMMPRIN is regulated by cyclophilin 60. J Biol Chem. 2005;280:27866–27871.
   PubMed Web of Science ®Google Scholar
• Song F, Zhang X, Ren X-B, et al. Cyclophilin A (CyPA) induces chemotaxis independent of its peptidylprolyl Cis-trans isomerase activity. J Biol Chem. 2011;286:8197–8203.
   PubMed Web of Science ®Google Scholar
• Shi W-P, Ju D, Li H, et al. CD147 promotes CXCL1 expression and modulates liver fibrogenesis. Int J Mol Sci. 2018;19:E1145.
   PubMed Web of Science ®Google Scholar
• Li H-Y, Ju D, Zhang D-W, et al. Activation of TGF-β1-CD147 positive feedback loop in hepatic stellate cells promotes liver fibrosis. Sci Rep. 2015;5:16552.
   PubMed Web of Science ®Google Scholar
• Zhang D-W, Zhao Y-X, Wei D, et al. HAb18G/CD147 promotes activation of hepatic stellate cells and is a target for antibody therapy of liver fibrosis. J Hepatol. 2012;57:1283–1291.
   PubMed Web of Science ®Google Scholar
• Iordanskaia T, Malesevic M, Fischer G, et al. Targeting extracellular cyclophilins ameliorates disease progression in experimental biliary atresia. Mol Med. 2015;21:657–664.
   PubMed Web of Science ®Google Scholar
• Stemmy EJ, Balsley MA, Jurjus RA, et al. Blocking cyclophilins in the chronic phase of asthma reduces the persistence of leukocytes and disease reactivation. Am J Respir Cell Mol Biol. 2011;45:991–998.
   PubMed Web of Science ®Google Scholar
• Seizer P, Klingel K, Sauter M, et al. Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3-induced myocarditis. J Mol Cell Cardiol. 2012;53:6–14.
   PubMed Web of Science ®Google Scholar
• Wang L, Jia J, Wang C, et al. Inhibition of synovitis and joint destruction by a new single domain antibody specific for cyclophilin A in two different mouse models of rheumatoid arthritis. Arthritis Res Ther. 2013;15:R208.
   PubMed Web of Science ®Google Scholar
• Lu G, Jia Z, Zu Q, et al. Inhibition of the cyclophilin A–CD147 interaction attenuates right ventricular injury and dysfunction after acute pulmonary embolism in rats. J Biol Chem. 2018;293:12199–12208.
   Google Scholar
• Satoh K, Nigro P, Matoba T, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med. 2009;15:649–656.
   PubMed Web of Science ®Google Scholar
• Satoh K, Nigro P, Zeidan A, et al. Cyclophilin A promotes cardiac hypertrophy in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2011;31:1116–1123.
   PubMed Web of Science ®Google Scholar
• Nigro P, Satoh K, O’Dell MR, et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E–deficient mice. J Exp Med. 2011;208:53–66.
   PubMed Web of Science ®Google Scholar
• Von Ungern-Sternberg SNI, Vogel S, Walker-Allgaier B, et al. Extracellular cyclophilin a augments platelet-dependent thrombosis and thromboinflammation. Thromb Haemost. 2017;117:2063–2078.
   PubMed Web of Science ®Google Scholar
• Pasetto L, Pozzi S, Castelnovo M, et al. Targeting extracellular cyclophilin A reduces neuroinflammation and extends survival in a mouse model of amyotrophic lateral sclerosis. J Neurosci. 2017;37:1413–1427.
   PubMed Web of Science ®Google Scholar
• Chang C-S, Su S-L, Kuo C-L, et al. Cyclophilin A: a predictive biomarker of carotid stenosis in cerebral ischemic stroke. Curr Neurovasc Res. 2018;15:111–119.
   PubMed Web of Science ®Google Scholar
• Kröller-Schön S, Steven S, Kossmann S, et al. Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species—studies in white blood cells and in animal models. Antioxid Redox Signal. 2014;20:247–266.
   PubMed Web of Science ®Google Scholar
• Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125–172.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Boudko S, Bächinger HP. Ziploc-ing the structure: triple helix formation is coordinated by rough endoplasmic reticulum resident PPIases. Biochim Biophys Acta. 2015;1850:1983–1993.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Mizuno K, Bächinger HP. Ziploc-ing the structure 2.0: endoplasmic reticulum-resident peptidyl prolyl isomerases show different activities toward hydroxyproline. J Biol Chem. 2017;292:9273–9282.
   PubMed Web of Science ®Google Scholar
• Gjaltema RAF, Bank RA. Molecular insights into prolyl and lysyl hydroxylation of fibrillar collagens in health and disease. Crit Rev Biochem Mol Biol. 2017;52:74–95.
   PubMed Web of Science ®Google Scholar
• Terajima M, Taga Y, Chen Y, et al. Cyclophilin-B modulates collagen cross-linking by differentially affecting lysine hydroxylation in the helical and telopeptidyl domains of tendon type I collagen. J Biol Chem. 2016;291:9501–9512.
   PubMed Web of Science ®Google Scholar
• Cabral WA, Perdivara I, Weis MA, et al. Abnormal type I collagen post-translational modification and crosslinking in a cyclophilin B KO mouse model of recessive osteogenesis imperfecta. PLoS Genet. 2014;10:e1004465.
   PubMed Web of Science ®Google Scholar
• Sarkar SK, Young PE, Sullivan CE, et al. Detection of cis and trans X-Pro peptide bonds in proteins by 13C NMR: application to collagen. Proc Natl Acad Sci. 1984;81:4800–4803.
   PubMed Web of Science ®Google Scholar
• Terajima M, Taga Y, Cabral WA, et al. Cyclophilin B control of lysine post-translational modifications of skin type I collagen. PLOS Genet. 2019;15:e1008196.
   PubMed Web of Science ®Google Scholar
• Choi JW, Sutor SL, Lindquist L, et al. Severe osteogenesis imperfecta in cyclophilin B-deficient mice. PLoS Genet. 2009;5:e1000750.
   PubMed Web of Science ®Google Scholar
• Pyott SM, Schwarze U, Christiansen HE, et al. Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes. Hum Mol Genet. 2011;20:1595–1609.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Vranka JA, Boudko SP, et al. Mutation in cyclophilin B that causes hyperelastosis cutis in american quarter horse does not affect peptidylprolyl cis-trans isomerase activity but shows altered cyclophilin B-protein interactions and affects collagen folding. J Biol Chem. 2012;287:22253–22265.
   PubMed Web of Science ®Google Scholar
• Cunningham J. Posttransplantation bone disease. Transplantation. 2005;79:629–634.
   PubMed Web of Science ®Google Scholar
• Shimizu C, Fujita T, Fuke Y, et al. Effects of cyclosporine on bone mineral density in patients with glucocorticoid-dependent nephrotic syndrome in remission. Int Urol Nephrol. 2013;45:803–808.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Aroldi A. Osteoporosis after organ transplantation. Lancet. 2001;357:1623.
   PubMedGoogle Scholar
• Steinmann B, Bruckner P, Superti-Furga A. Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase. J Biol Chem. 1991;266:1299–1303.
   PubMed Web of Science ®Google Scholar
• Nakamuta M, Kohjima M, Fukushima M, et al. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. Transplant Proc. 2005;37:4598–4602.
   PubMed Web of Science ®Google Scholar
• Kohjima M, Enjoji M, Higuchi N, et al. NIM811, a nonimmunosuppressive cyclosporine analogue, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int. 2007;27:1273–1281.
   PubMed Web of Science ®Google Scholar
• Scorneaux B, Thomas G, Hopkins S, et al. The effects of SCY-635, a nonimmunosuppressive cyclosporine analog on stellate cell proliferation, collagen synthesis, TIMP-1 and collagenase production. Hepatology. 2010;52:183.
   PubMedGoogle Scholar
• Lie TS, Preissinger H, Bach M, et al. The protective effect of cyclosporine against cirrhotic alteration of the liver. Surgery. 1991;110:847–853.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Wang T, et al. N-methyl-4-isoleucine cyclosporine attenuates CCl 4 -induced liver fibrosis in rats by interacting with cyclophilin B and D. J Gastroenterol Hepatol. 2011;26:558–567.
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Ludwig J, Lindor KD, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med. 1990;322:1419–1424.
   PubMed Web of Science ®Google Scholar
• Lombard M, Portmann B, Neuberger J, et al. Cyclosporin a treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology. 1993;104:519–526.
   PubMed Web of Science ®Google Scholar